Literature DB >> 24666369

A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry.

Jerry L Campbell1, Melvin E Andersen, Harvey J Clewell.   

Abstract

A PBPK model for naphthalene in the rat and human that incorporates a hybrid CFD-PBPK description of the upper respiratory tract was developed to support cross-species dosimetry comparisons of naphthalene concentrations and tissue normalized rate of metabolism in the nasal respiratory and olfactory epithelium, lung and liver. In vitro measurements of metabolic rates from microsomal incubations published for rat and monkey (surrogate for human) were scaled to the specific tissue based on the tissue microsomal content and volume of tissue. The model reproduces time courses for naphthalene blood concentrations from intravenous and inhalation exposures in rats and upper respiratory tract extraction data in both naïve rats and rats pre-treated to inhibit nasal metabolism. This naphthalene model was applied to estimate human equivalent inhalation concentrations (HECs) corresponding to several NOAELs or LOAELs for the non-cancer effects of naphthalene in rats. Two approaches for cross-species extrapolation were compared: (1) equivalence based on tissue naphthalene concentration and (2) equivalence based on amount metabolized per minute (normalized to tissue volume). At the NOAEL of 0.1 ppm, the regional gas dosimetry ratio (RGDR) based on naphthalene concentration was 0.18 for the dorsal olfactory region; however, the RGDR rises to 5.4 when based on the normalized amount metabolized due to the lower of expression of CYP isozymes in the nasal epithelium of primates and humans. The resulting HEC is 0.12 ppm (0.63 mg/m(3)) continuous exposure at the rat NOAEL of 0.1 ppm (6 h/day, 5 days/week).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24666369     DOI: 10.3109/08958378.2014.896059

Source DB:  PubMed          Journal:  Inhal Toxicol        ISSN: 0895-8378            Impact factor:   2.724


  11 in total

1.  Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data requirements: An international workshop report.

Authors:  Amy J Clippinger; David Allen; Annie M Jarabek; Marco Corvaro; Marianna Gaça; Sean Gehen; Jon A Hotchkiss; Grace Patlewicz; Jodie Melbourne; Paul Hinderliter; Miyoung Yoon; Dongeun Huh; Anna Lowit; Barbara Buckley; Michael Bartels; Kelly BéruBé; Daniel M Wilson; Ian Indans; Mathieu Vinken
Journal:  Toxicol In Vitro       Date:  2017-12-22       Impact factor: 3.500

2.  A Physiologically Based Pharmacokinetic Model for Naphthalene With Inhalation and Skin Routes of Exposure.

Authors:  Dustin F Kapraun; Paul M Schlosser; Leena A Nylander-French; David Kim; Erin E Yost; Ingrid L Druwe
Journal:  Toxicol Sci       Date:  2020-10-01       Impact factor: 4.849

Review 3.  Hypothesis-based weight-of-evidence evaluation and risk assessment for naphthalene carcinogenesis.

Authors:  Lisa A Bailey; Marc A Nascarella; Laura E Kerper; Lorenz R Rhomberg
Journal:  Crit Rev Toxicol       Date:  2015-09-07       Impact factor: 5.635

4.  Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled Drugs.

Authors:  E Boger; N Evans; M Chappell; A Lundqvist; P Ewing; A Wigenborg; M Fridén
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-04-14

5.  Human CYP2A13 and CYP2F1 Mediate Naphthalene Toxicity in the Lung and Nasal Mucosa of CYP2A13/2F1-Humanized Mice.

Authors:  Lei Li; Sarah Carratt; Matthew Hartog; Nataliia Kovalchik; Kunzhi Jia; Yanan Wang; Qing-Yu Zhang; Patricia Edwards; Laura Van Winkle; Xinxin Ding
Journal:  Environ Health Perspect       Date:  2017-06-08       Impact factor: 9.031

6.  Ex vivo real-time monitoring of volatile metabolites resulting from nasal odorant metabolism.

Authors:  Aline Robert-Hazotte; Rachel Schoumacker; Etienne Semon; Loïc Briand; Elisabeth Guichard; Jean-Luc Le Quéré; Philippe Faure; Jean-Marie Heydel
Journal:  Sci Rep       Date:  2019-02-21       Impact factor: 4.379

7.  Health Effects of Naphthalene Exposure: A Systematic Evidence Map and Analysis of Potential Considerations for Dose-Response Evaluation.

Authors:  Erin E Yost; Audrey Galizia; Dustin F Kapraun; Amanda S Persad; Suryanarayana V Vulimiri; Michelle Angrish; Janice S Lee; Ingrid L Druwe
Journal:  Environ Health Perspect       Date:  2021-07-12       Impact factor: 9.031

8.  A hybrid modeling approach for assessing mechanistic models of small molecule partitioning in vivo using a machine learning-integrated modeling platform.

Authors:  Victor Antontsev; Aditya Jagarapu; Yogesh Bundey; Hypatia Hou; Maksim Khotimchenko; Jason Walsh; Jyotika Varshney
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

9.  Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform.

Authors:  Kaushik Chakravarty; Victor G Antontsev; Maksim Khotimchenko; Nilesh Gupta; Aditya Jagarapu; Yogesh Bundey; Hypatia Hou; Neha Maharao; Jyotika Varshney
Journal:  Molecules       Date:  2021-03-29       Impact factor: 4.411

10.  A comprehensive physiologically based pharmacokinetic (PBPK) model for nicotine in humans from using nicotine-containing products with different routes of exposure.

Authors:  Ali A Rostami; Jerry L Campbell; Yezdi B Pithawalla; Hamideh Pourhashem; Raheema S Muhammad-Kah; Mohamadi A Sarkar; Jianmin Liu; Willie J McKinney; Robinan Gentry; Maria Gogova
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.